Targeted Therapy vs. Standard Treatment: PsA Infection Risk Comparison

Okay, here’s a breakdown of the provided text, summarizing the key findings and ⁢data. I’ll focus on clarity and conciseness.

Study ⁤summary:⁤ Combination Targeted therapy (CTT) for Psoriatic Arthritis⁢ (PsA)

This study investigated the use and⁤ safety of combination targeted therapy (CTT) – using two or more targeted therapies simultaneously – in ⁢patients with psoriatic arthritis ⁣(PsA). While CTT has shown promise in other conditions,‍ data on its real-world application and safety in PsA has been limited.

Key Findings:

* Prevalence: CTT was used in a small percentage of PsA patients (1.0% received 2 or more targeted ⁤therapy classes).
* Common Regimens: The most frequent CTT combinations involved:
* TNF-α inhibitor + apremilast (34.8%-37.3%)
⁤ ‍ ⁤* IL-17⁢ inhibitor + apremilast (27.1%-28.8%)
* Infection Rates: Serious infection rates were calculated for patients on CTT at 3, 4, and 6 months.
* Safety: After adjusting for potential confounding ⁤factors ⁤(age, sex, therapy duration, comorbidity), the⁣ study found no statistically critically important difference in the risk of serious infection between patients receiving CTT and those receiving standard therapy at 3, 4, or 6‍ months. This was ⁣consistent with results⁤ from propensity score matching.

Study Methodology:

*⁣ Data Source: IBM MarketScan Commercial Claims Database ⁣(2015-2024)
* patient Identification: A validated claims algorithm was used to identify adults with PsA.
* Study ⁢Groups: Patients were divided into a standard therapy group and a CTT group, with a 2:1 matching ratio.
* Sample size: 82,399 eligible individuals, with 39,101 in the standard therapy ‍cohort and 200 in⁣ the CTT cohort at⁣ 6 months.

In essence, ⁢the study suggests that CTT for PsA, while not widely used, does not appear to carry a significantly higher ⁤risk of serious infection compared to standard therapy.